Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

NCT03987308 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

115

Enrollment

OTHER_GOV

Sponsor class

Conditions

Type 2 Diabetic Patients
T2DM (Type 2 Diabetes Mellitus)
T2DM

Interventions

DRUG: Beinaglutide
DRUG: Insulin aspart

Sponsor

Beijing Hospital